INTRODUCTION
In recent years, it has become increasingly apparent that cellmediated immune responses, particularly those involving human immunodeficiency virus 1 (HIV-1)-specific CD8 + cytotoxic T lymphocytes (CTLs), play a key role in control of both acute and chronic HIV-1 infections (reviewed by Letvin, 2005) . The ability to elicit potent cellular immune responses has therefore become a priority for HIV-1 vaccine candidates. The goal of T-cell vaccines is to generate longlived memory CD8 cells capable of recognizing and rapidly expanding to combat viral infection.
The problematic stimulation of neutralizing antibodies in HIV-1 infection (Moore et al., 1995) , the recent failure of a recombinant gp120 glycoprotein to demonstrate vaccine efficacy in a phase III human clinical trial (Gilbert et al., 2005) and the inability of traditional vaccine approaches to generate a suitable and safe vaccine for HIV-1 (Baba et al., 1995; Murphey-Corb et al., 1989; Whitney & Ruprecht, 2004) have prompted the quest for the development of novel vaccine strategies. Among these, the most promising are the use of plasmid DNA and live recombinant vectors, either alone or as part of heterologous prime-boost combinations. Although plasmid DNAs have been less immunogenic in early-phase clinical testing in humans than in laboratory animals (MacGregor et al., 1998; McConkey et al., 2003) , a number of changes in plasmid DNA constructs have been shown to increase their immunogenicity (Donnelly et al., 2005) . Live recombinant vaccines that express HIV-1 immunogens have proven generally to stimulate strong CD4 + and CD8 + T-cell responses and neutralizing antibodies in non-human primates compared with whole killed vaccines, virus-like particles and subunit vaccines (Amara et al., 2001; Barouch et al., 2001; Horton et al., 2002; Seth et al., 2000 ; reviewed by Letvin et al., 2002; McMichael & Hanke, 2003) . Although live recombinant vectors are central to the development of new vaccine strategies against HIV-1, their utilization as vaccine candidates in humans is hampered due to problems related to pre-existing immunity, inefficient antigen delivery or presentation and toxicity issues, especially for immunocompromised individuals (Redfield et al., 1987) . Therefore, there is an urgent need to develop new live-vaccine vectors that are capable of enhancing antigen presentation and eliciting potent immune responses without the risk of developing disease in humans.
In this study, we describe a novel, non-pathogenic, protozoan parasitic vector, Leishmania tarentolae, as a recombinant HIV-1 vaccine candidate to improve the efficacy of HIV vaccine strategies. L. tarentolae has several features that make it very attractive as the basis for an effective recombinant HIV vaccine. We have shown recently that L. tarentolae efficiently targets antigen-presenting cells (APCs) (e.g. macrophages and dendritic cells) and lymphoid organs and that it activates the process of dendritic cell maturation (Breton et al., 2005) . Unlike other pathogenic Leishmania strains, L. tarentolae lacks the potential to replicate within the targeted APCs and is eliminated after several days from the infected murine host (Breton et al., 2005) . Nevertheless, L. tarentolae can elicit Tcell proliferation and the production of gamma interferon (IFN-c), skewing the T-cell response towards a Th1-cell phenotype, and it provides inflammatory responses for the APC and acts as an immunostimulatory adjuvant (Breton et al., 2005) . In the present study, we developed a recombinant L. tarentolae strain expressing high levels of full-length HIV-1 Gag and evaluated its ability to elicit HIV-1 Gag-specific T-cell responses in mice upon HIV antigen stimulation. Moreover, we immunized human lymphoid tissue cultured ex vivo that can be infected by both Leishmania and HIV-1 (Zhao et al., 2004) to assess the ability of the recombinant L. tarentolae-Gag vaccine vector to protect against HIV-1 infection. Such a system has not been used before to evaluate the protective efficacy of vaccine candidates.
METHODS
Parasite growth and transfections. The L. tarentolae Tar II strain (ATCC 30267) was grown in SDM-79 medium (Brun & Schonenberger, 1979) supplemented with 10 % heat-inactivated fetal bovine serum (FBS) (Multicell) and 5 mg haemin ml 21 . Leishmania transfections were carried out by electroporation as described elsewhere (Papadopoulou et al., 1992) . Approximately 10-15 mg DNA was used for transfections and cells were selected with G-418 (40 mg ml 21 ; Sigma).
Plasmid construction and DNA manipulations. The pNEO-Gag expression vector was made as follows. First, the intergenic region of the a-tubulin gene necessary for mRNA processing was inserted into the XhoI/XbaI sites of pSP72 (Promega). Then, the neomycin phosphotransferase (NEO) gene with an additional intergenic region of the a-tubulin gene was cloned as a KpnI-EcoRI fragment into the respective sites of vector pSPa. The 18S rRNA gene promoter sequence, described elsewhere (Yan et al., 1999) , was cloned in the NdeI site of the above vector. Finally, a 1.6 kb fragment containing the HIV-1 gag gene was amplified using Pwo polymerase (Roche) from pNL4.3 (Adachi et al., 1986) , a full-length HIV-1 proviral molecular clone, using the following set of primers 59Gag (XbaI): 59-CGTCTAGAAGGAGAGAGATGG-39 and 39Gag (KpnI):
59-GGGGTACCTTTATTGTGACG-39, and then introduced as an XbaI-KpnI insert between the two a-tubulin intergenic regions to generate vector pNEO-Gag. Southern and Western blot analyses were performed to test for the presence of Gag-expressing vector and to evaluate Gag protein expression using standard procedures. IFN-c ELISPOT assay. To evaluate the frequency of T cells producing IFN-c, we used an enzyme-linked immunosorbent spot (ELISPOT) assay as described elsewhere (Mashishi & Gray, 2002) . Briefly, 96-well multiscreen plates (Millipore) were coated by overnight incubation at 4 uC with rat anti-mouse IFN-c capture monoclonal antibody (clone R4-6A2; BD Pharmingen) at a concentration of 10 mg ml 21 in PBS. Splenocytes were harvested from mice at 2, 4, 8 and 12 weeks after immunization with recombinant L. tarentolae. Cells (1610 5 per well) were plated in triplicate in a 100 ml final volume with medium alone or stimulated with a pool of overlapping Gag peptides in complete RPMI 1640. HIV-1 Gag peptides of 9, 15 or 20 aa in length were obtained from the AIDS Research and Reference Reagent Program, NIH (Rockville, MD, USA), and used for stimulation at a final concentration of 10 mM. After a 24 h incubation at 37 uC in 5 % CO 2 , the plates were washed with PBS containing 0.05 % Tween (PBST) and incubated for 6 h at room temperature with a secondary biotinylated rat anti-mouse IFN-c antibody (XMG1.2; BD Pharmingen). Plates were washed six times with PBS and streptavidin-alkaline phosphatase (diluted 1 : 100 000; Sigma) was added. After incubation for 2 h, plates were washed and developed with NBT/BCIP (Bio-Rad). Plates were air-dried and the spots were counted using a stereomicroscope (Carl Zeiss Canada) at 406 magnification. An ELISPOT assay was also performed on CD4 + T-cell-depleted splenocytes using the panning method (Norton, 1997) . The mean number of spots from triplicate wells was calculated for each animal and adjusted to represent the mean number of spots per 10 6 spleen cells. Data are presented as spot forming units (s.f.u.) per 10 6 spleen cells from five animals per group.
Anti-p24 antibody titres. Serum was collected from individual mice at 8 weeks post-immunization and anti-p24 antibody titres were determined by ELISA. Ninety-six-well plates (ImmunoPlate Maxisorp; Nunc) were coated by overnight incubation at 4 uC with 50 ng p24 per well. Plates were blocked with PBS plus 5 % BSA for 2 h at room temperature and then washed with PBST. Sera were diluted in PBS from 1 : 100 to 1 : 500 and 100 ml peroxidase-conjugated rabbit anti-mouse IgG antibody (Sigma) was added and incubated for 1 h at room temperature. After at least five washes, plates were developed with 3,39,5,59-tetramethylbenzidine peroxidase substrate (Research Diagnostics). Reactions were stopped with 2 M H 2 SO 4 and the absorbance was measured at 450 nm using an Organon Teknika Microwell system.
Delivery of L. tarentolae and NL4.3 HIV-1 strain to human tonsillar tissue blocks. Human tonsils were obtained from patients who underwent routine tonsillectomy. Tonsils were washed thoroughly with PBS containing antibiotics, dissected into small pieces of~2-3 mm 3 and cultured in RPMI 1640 supplemented with FBS and antibiotics on collagen sponge gels at the air-liquid interface at 37 uC in a 5 % CO 2 atmosphere as described previously (Zhao et al., 2004) . After 24 h, different concentrations (1610  3 ,  1610 4 , 5610 4 , 1610 5 and 5610 5 cells) of recombinant L. tarentolae expressing HIV-1 Gag were added on top of the tissue blocks and 3 h later the tonsillar pieces were washed with PBS and kept in culture for up to 2 weeks. At~3 weeks after immunization with recombinant L. tarentolae, 5 ng NL4.3 HIV-1 strain was applied on top of the tissue blocks. Aliquots of supernatants were harvested 6 days after infective HIV-1 challenge and a sandwich ELISA was performed on supernatants to quantify p24 production and monitor HIV replication. The p24 antibody capture assay has been described previously (Bounou et al., 2002) . It should be noted that separate blocks of human tonsillar tissue from six different donors were tested (i.e. a total of eight tissue blocks in four different wells) to normalize for variation in cell number and composition and to allow comparison of immunized and non-immunized tissue.
Statistical analyses. Data were expressed as means±SEM. The statistical significance of differences between groups was analysed using a paired Student's t-test. A P value of less than 0.05 was considered significant.
RESULTS
Generation of recombinant L. tarentolae expressing high levels of HIV-1 Gag
To determine whether L. tarentolae could express HIV-1 proteins efficiently, we generated a Gag-encoding expression vector, pNEO-Gag, that was introduced by electroporation into the non-pathogenic protozoan parasite L. tarentolae as described in Methods. In pNEO-Gag, the expression of the HIV-1 gag gene is under the control of the RNA pol I 18S rRNA gene promoter (Fig. 1a) , which allows high levels of expression. Western blot analysis using an anti-p24 antibody showed that recombinant L. tarentolae transformed with the HIV-1 Gag expression vector showed high levels of expression of the full-length 55 kDa Gag protein (Fig. 1b) . Remarkably, the HIV-1 Gag polyprotein was processed into its other proteolytic products in Leishmania, such as p24, in a similar fashion to HIV-1 Gag from H9 HIV-1-infected cells. These results showed the successful expression of the full-length HIV-1 Gag protein in the nonpathogenic L. tarentolae and suggested that Gag polyprotein can be processed by proteases within the parasite.
Immunization with recombinant L. tarentolae expressing HIV-1 Gag elicits HIV-1-specific cell proliferative responses
To determine whether administration of the recombinant L. tarentolae vaccine vector stimulated T-cell responses, splenocytes harvested from immunized mice were first assessed for antigen-stimulated proliferation. Splenocytes were cultured with various concentrations of a recombinant p24 Gag protein and proliferative responses were measured by [ 3 H]thymidine incorporation. An antigen-specific, dosedependent proliferation was observed in splenocytes from mice immunized with recombinant L. tarentolae at different time points post-immunization. Proliferation of splenic cells from mice immunized with recombinant L. tarentolae was increased by~12-fold in response to the highest p24 dose (50 pg ml 21 ) (Fig. 2a) . No p24-specific proliferative responses were observed in splenocytes of mice immunized with wild-type L. tarentolae (Fig. 2a) . Interestingly, 
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Leishmania is mediated by trans-splicing and polyadenylation and requires polypyrimidine-rich sequences and an AG spliceacceptor site (Clayton, 2002 antigen-stimulated proliferation was still observed at 12 weeks post-immunization and at slightly increased levels (Fig. 2b) .
Immunization with recombinant L. tarentolae elicits HIV-1-specific CD8 + T cells secreting IFN-c
Vaccine-elicited immune responses were monitored in BALB/c mice using an IFN-c ELISPOT assay. Splenocytes were harvested from mice at weeks 2, 4, 8 and 12 after immunization with recombinant L. tarentolae and then stimulated with a pool of overlapping peptides representing a processed form of the HIV-1 Gag protein. Our results on total splenocytes indicated an important increase in the number of IFN-c-producing T cells following stimulation with the Gag peptide pool compared with unstimulated splenocytes (Fig. 3a) . The peak response was elicited at Splenocytes of each group were pooled and ELISPOT assays were performed in triplicate as indicated in Methods.
splenocytes), even 12 weeks after immunization with recombinant L. tarentolae (Fig. 3a) .
To evaluate whether specific HIV-1 Gag epitopes could stimulate T cells to produce IFN-c, we used five different pools (P1-P5) of 15 overlapping HIV-1 Gag peptides each. These peptides were 9-20 aa long and overlapped by~8-11 residues. Peptide pool 4 (P4) was capable of inducing a greater stimulation of IFN-c-producing T cells in splenocytes isolated from BALB/c immunized mice at week 12 post-immunization (Fig. 3b) . Peptides in pool P4 cover a region of the HIV-1 Gag protein between aa 281 and 430. This region includes the end of the capsid (p24) and part of the nucleocapsid (p7).
The functional capacity of recombinant L. tarentolae to induce HIV-1 Gag-specific CD8 + T-cell responses was also determined. CD4 + T cells were selectively depleted from the splenocyte T-cell population by the panning approach (Norton, 1997) prior to assaying these cells in an IFN-c ELISPOT assay. Depletion of CD4 + T cells had no significant effect on the Gag-specific-induced IFN-c response (Fig. 3c) , suggesting that recombinant L. tarentolae-elicited HIV-1-specific CD8
+ T cells were capable of secreting IFN-c in response to HIV-1 Gag peptide stimulation.
A booster immunization with recombinant L. tarentolae stimulates the development of longlasting immune responses
Protection following viral clearance or successful immunization requires the generation and maintenance of longlived, antigen-specific CD4 + Th cells (reviewed by Klenerman & Hill, 2005) . CD4 + Th cells are also critical for the development of CD8 + T-cell memory (Janssen et al., 2003; Shedlock & Shen, 2003) . We first measured the CD4 + effector memory response to HIV-1 Gag in mice immunized once with the recombinant L. tarentolae-Gag vaccine vector. Six months after immunization, bulk splenocytes were isolated, stimulated with HIV-1 p24 protein and stained with TC-conjugated monoclonal antibodies to CD4, FITCconjugated antibodies to CD69 and CD44, and PE-labelled antibodies to CD25 and CD62L, and analysed by flow cytometry. CD25 and CD69 are cell-surface markers that are expressed in activated Th1 subpopulations. CD44 is a surface protein required for lymphocyte extravasation to inflammatory sites and its upregulation is a marker for all memory T cells (DeGrendele et al., 1997). CD62L is a lymph node homing receptor that is downregulated upon activation of T-cell populations (Andersson et al., 1994) . Upon antigen stimulation, approximately 22 % of the CD4 + cells were effector cells, CD44
High /CD62L Low , compared with 14 % in naive mice (Table 1) . A significant proportion of the CD4 + T cells in vaccinated mice expressed the activation markers CD25 and CD69 (~15 % and~11 %, respectively) ( Table 1) .
To determine whether T-cell responses could be enhanced following a booster immunization, mice were reinjected i.p.
with a second dose of recombinant L. tarentolae-Gag 1 month after the first immunization. Five months after the second immunization, bulk splenocytes were isolated, stimulated with HIV-1 p24 and stained with specific antibodies to measure antigen-specific CD4 + Th cells by FACS analysis as described in Methods. Following antigen stimulation with HIV-1 p24, approximately 46 % of the CD4 + T cells were effector cells (CD44 High /CD62L Low ), a 2-fold increase compared with mice immunized with a single i.p. dose of the recombinant vaccine (Table 1 ). The expression of CD25 and CD69 activation markers on the surface of CD4 + T cells was also increased by approximately 2-fold in boosted animals following stimulation with p24 Gag (Table 1) . Thus, our data indicated that a second encounter with the HIV-1 Gag antigen stimulates the proliferation of effector memory CD4 + T cells.
Immunization with recombinant L. tarentolae expressing HIV-1 Gag elicits low antibody responses against HIV-1 Gag
We evaluated the production of anti-Gag-specific antibodies in the serum of L. tarentolae-Gag-immunized mice. Various dilutions (1 : 100, 1 : 250, 1 : 500) were used of sera obtained at 4 and 8 weeks following i.p. immunization with recombinant L. tarentolae expressing HIV-1 Gag protein.
A p24 ELISA was used to measure the IgG p24-specific immune responses. No antibodies were found in sera after only a single injection with recombinant L. tarentolae (Fig. 4 and data not shown). However, we observed a low antibody response in the 1 : 100 dilution of sera collected 4 weeks after a booster immunization with recombinant L. tarentolae (Fig. 4) . Thus, to trigger a specific humoral response against the HIV-1 Gag protein, a secondary encounter with the antigen following a booster immunization with recombinant L. tarentolae is required.
Immunization of human lymphoid tissue with recombinant L. tarentolae elicits an important decrease in virus replication following exposure to HIV-1
With the exception of the rhesus macaque model, no other models are being used to evaluate protective immune responses against simian/human immunodeficiency virus infection. Here, we evaluated whether immunization of ex vivo human tonsillar tissue with the Gag-expressing L. tarentolae vector could elicit protection following exposure to HIV-1 infection. This system was described initially as a model to study HIV-1 infection (Glushakova et al., 1995) . We recently demonstrated that Leishmania donovani can infect human lymphoid tissue (Zhao et al., 2004) . Here, we showed by both microscopic examination and FACS analysis that non-pathogenic L. tarentolae could be delivered to human lymphoid tissue (Fig. 5a, b) . Indeed, L. tarentolae was found in approximately 40 % of the CD14 + cells (i.e. monocytes and macrophages) within the human tonsils (Fig. 5a) . Eight separate blocks of human tonsillar tissue derived from each donor were used to allow comparison of immunized tissue with Gag-expressing L. tarentolae and unimmunized tissue (L. tarentolae wild-type). Three weeks after immunization, tonsillar tissues were infected with the NL4.3 HIV-1 strain. Aliquots of supernatants were harvested 6 days after HIV-1 infection and an ELISA recombinant L. tarentolae cells within a 1 month interval (X). Eight weeks after the first i.p. immunization or 4 weeks after booster immunization, mice were bled and serial dilutions (1 : 100, 1 : 250 and 1 : 500) from pooled sera from each immunization group were used to determine antibody titres against HIV-1 Gag protein by ELISA. Data represent means±SEM of five mice per group and each assay was performed in triplicate. sandwich was performed to quantify p24 production and to monitor HIV-1 replication. Immunization of human tonsillar tissues with recombinant L. tarentolae resulted in an~75 % decrease in virus replication compared with unimmunized tissue (Fig. 5c ). Immunization with an increased dose of Gag-expressing L. tarentolae (10 5 -10 6 ) resulted in a higher decrease in virus replication (Fig. 5c) . Interestingly, highly reproducible results were obtained with blocks of tonsillar tissue from six different donors where a 66-75 % decrease in virus replication was observed following immunization of tonsillar tissue blocks with 10 6 L. tarentolae cells and subsequent exposure to the NL4.3 HIV-1 strain at 3 weeks post-immunization (data not shown). To rule out the possibility that the parasite could make the tonsils less suitable host cells for HIV replication, by stimulating innate immunity for instance, we incubated the tonsillar material in parallel with wild-type L. tarentolae and a recombinant L. tarentolae expressing an irrelevant antigen, i.e. green fluorescent protein (GFP). These experiments showed that HIV-1 replication was not affected by the presence of the wild-type parasite (Fig. 5c ) or the parasite expressing GFP (data not shown).
The main targets for X4 HIV-1 (NL4.3) are CD4 T lymphocytes. We therefore tested whether the numbers of these target cells were the same for uninfected, L. tarentolaeimmunized and L. tarentolae-Gag-immunized tissue blocks. Our results indicated that there were no differences in the number of CD4 T cells between L. tarentolae-Gagimmunized and L. tarentolae-immunized tissue blocks (data not shown).
DISCUSSION
In this study, we demonstrated that a novel, live-vector vaccine of a non-pathogenic protozoan parasite, L. tarentolae, expressing full-length HIV-1 Gag protein was immunogenic in mice and, more importantly, that it elicited protective immune responses in human tonsillar tissue cultured ex vivo following exposure to HIV-1 infection. L. tarentolae is a lizard parasite that has never been associated with any pathology in humans and therefore safety or preexisting immunity issues in humans are not a major concern. Moreover, the strain has been shown to be nonpathogenic when injected into immunodeficient SCID mice (Breton et al., 2005) . Furthermore, recombinant L. tarentolae as a non-replicating, live-vector vaccine achieves only one round of infection, which makes it even safer for human use. In addition, L. tarentolae has several other features that may make it an effective HIV vaccine vector. L. tarentolae is an intracellular parasite that shares common target cells with HIV-1, e.g. macrophages and dendritic cells and secondary lymphoid organs (Breton et al., 2005) . Therefore, a recombinant L. tarentolae vaccine vector should mimic the processing, maturation and presentation of viral antigens seen during natural infection. A more efficient targeting of HIV-1 immunogens to APCs could enhance MHC/antigen-presentation functions and elicit a more potent stimulation of antigen-specific CD4 + Th cell and CD8 + CTL responses, which are critical for the control of HIV replication (Letvin, 2005) . In addition, L. tarentolae induces dendritic cell maturation and elicits CD4 + T-cell proliferation and the production of IFN-c, thereby driving Th1 cell polarization, which can be critical for the secondary expansion of memory CTLs (Breton et al., 2005) . Finally, L. tarentolae demonstrates a high cloning capacity, is capable of expressing a wide range of multiple foreign antigens and grows rapidly in a cell-free medium at low cost.
The optimal vaccine vector would produce the vaccine antigen in excess of its own proteins (so that the immune response focuses on the target antigen) and would primarily be produced in APCs for induction of CTL responses. The presence of the ribosomal promoter greatly enhances the expression of HIV-1 Gag in L. tarentolae. Recombinant L. tarentolae elicited HIV-specific CD8 + T-cell responses that were maximal 2 weeks after immunization. This peak immune response has also been described in mice immunized with adenoviral and vaccinia vectors (Barouch et al., 2003; Seaman et al., 2004) . CD8
+ T-cell activation and IFN-c production was higher in response to a specific pool of Gag peptides spanning the aa 281-430 region of the Gag protein, which corresponds to the end of the capsid (p24) and part of the nucleocapsid (p7). CD4 + T-cell depletion studies indicated that IFN-c-producing T cells were mainly of CD8 + type. Diverse evidence supports the importance of the cellular immune response in HIV containment. CTLs have been shown to play a particularly important role in the early control of HIV infection (Betts et al., 2001; Goulder et al., 2001; Jin et al., 1999; Schmitz et al., 1999) . Long-term non-progressors also have consistently higher levels of HIV CTLs than progressors (Harrer et al., 1996) . In addition, rhesus monkeys lacking CD8 + T cells fail to control simian immunodeficiency virus infection (Schmitz et al., 1999) . The ability of L. tarentolae to target macrophages and dendritic cells may explain the induction of T-cell activation. In recent years, it has become increasingly apparent that dendritic cells potentially link the innate and adaptive immune systems, coordinating the activation of strong cellular and humoral immunity (Granucci et al., 2003; Melief, 2003) .
Interestingly, in mice that have been immunized twice with recombinant L. tarentolae, 50 % of the HIV-1 Gag-specific CD4 + T cells within spleen cells were effector cells (CD44 High /CD62L Low ). Thus, these data suggest that recombinant L. tarentolae is able to elicit HIV-1-specific effector memory in vivo after re-encountering the antigen. Memory CD4 + T cells are critical for the development of CD8 + T-cell memory (Janssen et al., 2003; Shedlock & Shen, 2003) . In addition to the induction of effector T-cell responses by the recombinant L. tarentolae vaccine vector, a booster immunization with this live-vector vaccine elicited Gag-specific humoral responses. The production of antibodies against p24 is probably due to the activation of CD4 + T cells. It is likely that the use of recombinant L. tarentolae expressing HIV-1 Gag as part of a heterologous prime-boost strategy may be superior for eliciting memory T-cell and recall responses, as all of the secondary responses will focus on the viral immunogen alone and not on internal Leishmania proteins shared between the priming and boosting vectors. Heterologous prime-boost vaccine regimens have been reported to induce more potent T-cell and antibody responses against HIV-1 (Amara et al., 2001 ).
An important finding of our studies is that immunization of human tonsillar tissue blocks with recombinant L. tarentolae expressing HIV-1 Gag elicited more than a 75 % decrease in HIV-1 replication following exposure to HIV-1 infection. The highest decrease in virus replication was observed when an increased inoculum of recombinant L. tarentolae was used for immunization. This can be explained, as nonreplicating, live-vector vaccines typically require high doses and booster immunizations to achieve sufficient antigen to drive immune responses. Although further experiments are required to establish the link between the important decrease in virus replication seen only in immunized tonsillar tissue and the development of protective immunity, preliminary data indicated that there was no difference in the number of CD4 T cells between immunized and unimmunized tissue blocks, which suggests that elicitation of HIV-1 Gag-specific immune responses might be responsible for the observed phenotype. Our data support the possibility of using human tonsillar tissue as an ex vivo system to evaluate the protective efficacy of candidate vaccines towards HIV-1 infection. Previous reports have indicated that secondary lymphoid organs constitute preferred anatomical sites for HIV replication and propagation (Grivel et al., 2003) . Moreover, the human lymphoid tissue cultured ex vivo has been shown to preserve the general cytoarchitecture found in normal human lymphoid tissue, including a network of follicular dendritic cells, macrophages, CD4 + and CD8 + T lymphocytes and dendritic cells (Glushakova et al., 1995; Margolis et al., 1997) , hence permitting evaluation of cellular and humoral immune responses.
In summary, we have described a novel, live-vector vaccine, a recombinant L. tarentolae expressing HIV-1 Gag protein, which is capable of efficient delivery of HIV-1 immunogens to APCs and to lymphoid organs. We showed that this recombinant vaccine vector could induce HIV-1-specific CD8 + T-cell responses and that it stimulated long-lasting immunity by the production of effector memory CD4 + T cells. Moreover, this live-vector vaccine is safe for human use, which makes it an attractive candidate for a vaccination strategy not only against HIV-1 but also against other intracellular pathogens for which T-cell-mediated immunity is required for protection.
